2013

Senate Bill 486 Evaluation Team

CONSUMER REPORT CARD

SUMMARY:

The legislatively mandated deadline for report submission was July 1, 2013. There were 25 plans submitted to the State of California which posted them on their website for public consumption. These plans were read and graded by a 9-person evaluation team, scoring each plan based on published consumer criteria. There were:

- Four "A" grade plans;
- Three "B" grade plans;
- Zero "C" grade plan;
- One "D" grade plan; and
- Twenty "F" grade plans.
- In addition, Fourteen "F/Incomplete" grade plans were given for those manufacturers who did not submit plans by the legislatively mandated deadline of July 1 or did not submit plans whatsoever.

At least thirteen manufacturers resubmitted their 2010, 2011 or 2012 plans **verbatim** and those are indicated with an asterisk(*). Plans that were submitted **after** the legislatively mandated July 1 deadline are marked with a (∞).

Manufacturer	Score	Grade
Abbvie ∞ (Formerly Abbott Labs)	94	A
Amgen*	90	A
Bayer ∞	21	F
Biogen Idec	80	B
Bristol Meyers Squibb		
Orencia	80	B
Other drugs	0	F
Drugs in trial	43	F
CSL Behring*	2	F
Dr. Reddy's Lab∞	9	F
Eisai	62	D
Eli Lilly & Co.	13	F
EMD Serono*	93	A
Genentech/Roche	46	F
GlaxoSmithKline*	42	F
Janssen Biotech, Inc./ Johnson & Johnson	94	A
JHP *∞	3	F
Kadmon *	45	F
Merck *	32	F
Novartis		
Signifor	75	B
All Others	15	F
NPS	10	F
Perrigo*	5	F
Pfizer	20	F
Sandoz*	3	F
Sanofi-Aventis*	47	F
Teva (Neuro)*	22	F
Teva (Others)*	17	F
Viro*	11	F

HONORABLE MENTION:

- **Waste Management, Inc.**

Although they weren't subject to SB 486, they submitted a plan and earned an **honorable mention** from the SB 486 Evaluation Committee.

THE FOLLOWING DRUG MANUFACTURERS ARE IN VIOLATION OF STATE LAW DUE TO THE FACT THAT THEY **DID NOT** **SUBMIT** ANY PLANS TO THE STATE IN 2013 YET MAKE HOME INJECTABLE MEDICATION SUBJECT TO SB 486:

Manufacturer	**Grade**
Biovitrium (no plan on file since law went into effect in 2010)	F
Baxter (last plan on file: 2012, authored in 2010)	F
Dey Pharmaceuticals (last plan on file: 2011)	F
Ferring Pharmaceuticals (last submitted in 2011)	F
Grifols (last plan on file: 2011)	F
Hospira (last plan on file: 2011- claim they are not subject to SB 486)	F
InterMune (last plan on file: 2011)	F
Ipsen (last plan on file: 2011)	F
Novo Nordisk (last plan on file: 2011)	F
Questcor Pharmaceuticals (no plan on file since law went into effect in 2010)	F
Salix (last plan on file: 2012)	F
Shire HGT (last plan on file: 2012)	F
UCB, Inc. (last plan on file: 2012)	F
Zoegenix (no plan on file since law went into effect in 2010; manufacturer claims they have a proprietary "needle-fee" subcutaneous injection delivery system and aren't subject to SB 486)	F